Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Pancreatic adenocarcinoma

86 clinical trials

124 products

25 drugs

Clinical trial
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
Status: Recruiting, Estimated PCD: 2030-04-01
Product
CTX131
Product
Nab paclitaxel
Product
Gemcitabine
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Clinical trial
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Status: Active (not recruiting), Estimated PCD: 2022-12-08
Product
LOAd703
Clinical trial
Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Status: Active (not recruiting), Estimated PCD: 2023-08-22
Product
CDX-1140
Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Pembrolizumab
Product
MDNA11
Product
Chemotherapy
Product
CDX-301
Product
pembrolizumab
Product
TC-510
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-10-30
Product
Fludarabine
Product
Cyclophosphamide
Clinical trial
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Product
Naptumomab estafenatox
Product
Obinutuzumab
Product
IMM-1-104 Monotherapy
Clinical trial
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-01
Product
IMM-1-104
Clinical trial
An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-19
Product
RO7515629
Product
tocilizumab
Product
IMM-1-104 + modified Gemcitabine/nab-Paclitaxel
Clinical trial
A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Status: Recruiting, Estimated PCD: 2026-06-30
Product
ASP2138
Product
AZD0901
Product
5-Fluorouracil
Product
Leucovorin
Clinical trial
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.
Status: Recruiting, Estimated PCD: 2025-05-02
Product
Nanoliposomal Irinotecan
Product
l-leucovorin
Product
Irinotecan
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Product
JK08
Product
Atezolizumab
Product
BL-8040
Product
Selicrelumab
Product
Tiragolumab
Clinical trial
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-10-17
Product
Nab-Paclitaxel
Product
Oxaliplatin
Product
Fluorouracil
Product
Cobimetinib
Product
PEGPH20
Product
Bevacizumab
Product
RO6874281
Product
AB928
Product
Tocilizumab
Product
Nab-paclitaxel
Clinical trial
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-04-28
Product
VCN-01
Clinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Lurbinectedin
Product
Naptumomab estafenatox and Durvalumab
Clinical trial
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-13
Product
OBI-3424
Clinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-03-06
Product
AB011
Clinical trial
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
9-ING-41
Product
Carboplatin.
Product
Doxorubicin.
Product
Lomustine
Product
Paclitaxel.
Product
eryaspase
Clinical trial
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Status: Completed, Estimated PCD: 2021-08-30
Product
Irinotecan + 5-FU + Leucovorin
Product
SEA-CD40
Product
Gemcitabine + Abraxane
Clinical trial
AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer
Status: Completed, Estimated PCD: 2013-05-01
Product
AdV-tk
Product
Valacyclovir
Clinical trial
An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-27
Clinical trial
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Status: Completed, Estimated PCD: 2021-07-30
Product
EndoTAG-1
Product
MRTX1133
Product
MRTX1719
Clinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Status: Recruiting, Estimated PCD: 2026-04-30
Product
batiraxcept
Clinical trial
A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Terminated, Estimated PCD: 2023-08-14
Clinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2026-08-30
Clinical trial
A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Panitumumab
Product
Panitumumab-IRDye800
Clinical trial
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-10-31
Product
mFOLFIRINOX
Clinical trial
IntenSify: An Open-label Phase I Trial of the CYP3A Inhibitor Cobicistat and the Cytostatics Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma to Evaluate the Combination's Pharmacokinetics, Safety and Efficacy
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Cobicistat
Product
Gemcitabin
Drug
Atezolizumab
Drug
Tivozanib
Clinical trial
Cisplatin Based Regimen to Patients With Advanced Pancreatic Cancer and Homologous Recombination Deficiency
Status: Recruiting, Estimated PCD: 2025-10-31
Drug
Cisplatin
Clinical trial
Pancreatic-enzyme Replacement Therapy With Pancreaze (Pancrelipase) Delayed-release in Addition to Standard of Care for Borderline Resectable, Locally Advanced, and Advanced Pancreatic Adenocarcinoma Patients (PANCAX-3) With Cachexia and Exocrine Pancreatic Insufficiency
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Pancrelipase
Clinical trial
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-30
Product
CAdVEC
Clinical trial
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
Status: Completed, Estimated PCD: 2023-12-11
Product
Paricalcitol
Clinical trial
A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer
Status: Active (not recruiting), Estimated PCD: 2020-10-04
Drug
Gemcitabine
Product
Paclitaxel
Drug
Metformin
Clinical trial
The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Ferumoxytol
Clinical trial
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
Status: Active (not recruiting), Estimated PCD: 2023-09-16
Drug
Liposomal Irinotecan
Clinical trial
Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Drug
AN0025
Product
Olaparib
Product
Cediranib
Clinical trial
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Product
Retifanlimab
Drug
Abraxane
Clinical trial
Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2023-06-30
Product
Trametinib
Product
Ruxolitinib
Product
FOLFOX
Clinical trial
A Phase 1, Prospective, Standard Dose Escalation Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
PCX-12
Clinical trial
NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-04-15
Product
Capecitabine
Drug
5-FU
Product
Leucovorin Calcium
Drug
Losartan
Drug
mFOLFOX6
Clinical trial
Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
Status: Not yet recruiting, Estimated PCD: 2028-10-01
Product
Dostarlimab
Clinical trial
Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in Combination With Cadonilimab for First-Line Treatment of Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma : A Single-arm, Phase II Study
Status: Recruiting, Estimated PCD: 2026-08-30
Product
Nanoliposomal Irinotecan + Oxaliplatin + Capecitabine + Cadonilimab
Clinical trial
Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
mFOLFIRINOX or Gemcitabine / Nab-paclitaxel Followed by Pancreatectomy for Patients With Borderline Resectable Pancreatic Adenocarcinoma. A Pilot Feasibility Study.
Status: Recruiting, Estimated PCD: 2024-05-01
Drug
mFOLFIRINOX
Product
Gemcitabine + Nab-paclitaxel
Clinical trial
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic Cancer
Status: Completed, Estimated PCD: 2018-04-01
Product
Nelfinavir
Drug
Oregovomab
Clinical trial
A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma
Status: Terminated, Estimated PCD: 2021-08-30
Product
CV301
Drug
UTD1
Clinical trial
Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST)
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Autologous DC vaccine
Clinical trial
A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Zoledronic Acid
Clinical trial
A Phase I/Ib Pilot Trial, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Modified GCN+TTF
Clinical trial
Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal Cancer
Status: Completed, Estimated PCD: 2021-10-28
Product
VX15/2503
Product
Ipilimumab
Drug
T-VEC
Clinical trial
The Impact of Total Intravenous Anesthesia Following Cancer Surgery (TIVACS) Study
Status: Completed, Estimated PCD: 2024-01-26
Product
General Anesthesia
Clinical trial
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Autologous, engineered T Cells targeting TP53 R175H
Clinical trial
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
APL-5125
Clinical trial
A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)
Status: Terminated, Estimated PCD: 2023-08-16
Drug
Modified FOLFIRINOX
Drug
FOLFOXIRI
Drug
mFOLFOXIRI
Product
NIS793
Clinical trial
A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma
Status: Terminated, Estimated PCD: 2021-11-01
Drug
fluorouracil
Clinical trial
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Status: Completed, Estimated PCD: 2018-06-01
Product
Milestone 1
Product
Milestone 3: Targeted chemotherapy
Product
FOLFIRINOX chemotherapy
Product
Milestone 5
Product
Milestone 8
Clinical trial
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Floxuridine
Product
Heparinized Saline
Clinical trial
Phase 2 Study of Preoperative Chemotherapy With Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
Status: Completed, Estimated PCD: 2019-11-12
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
Spartalizumab
Clinical trial
Evaluation of Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 (HER 2) and Its Association With Clinicopathological Variables in Patients With Pancreatic Duct Adenocarcinoma in Upper Egypt
Status: Completed, Estimated PCD: 2020-08-31
Product
Immunohistochemical approach
Product
Tislelizumab
Clinical trial
Randomized Phase 2 Study of mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Patients With Locally Advanced Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-08-14
Clinical trial
A Phase I/II Study of Durvalumab (Medi 4736) and Stereotactic Ablative Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Phase Ib-II Study of Ramucirumab Combined With Standard Nab-paclitaxel and Gemcitabine as First-line Treatment in Patients With Advanced Pancreatic Adenocarcinoma
Status: Completed, Estimated PCD: 2022-06-17
Product
Ramucirumab
Clinical trial
PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy
Status: Active (not recruiting), Estimated PCD: 2022-04-05
Product
Niraparib + Nivolumab
Product
Niraparib + Ipilimumab
Clinical trial
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Completed, Estimated PCD: 2017-12-01
Product
Paclitaxel Albumin-Stabilized Nanoparticle
Clinical trial
Preoperative Treatment With mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for Borderline Resectable Pancreatic Adenocarcinoma: a Randomised Phase II Study (STEREOPAC)
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2020-08-03
Product
Tremelimumab
Clinical trial
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-12-10
Drug
Docetaxel
Drug
Erlotinib
Clinical trial
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
Status: Recruiting, Estimated PCD: 2029-01-15
Clinical trial
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors Including Triple-Negative Breast Cancer and Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-05-01
Product
AGX101
Clinical trial
A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Romidepsin
Product
Azacitidine
Clinical trial
Phase 2 Gene Therapy Trial of Locally Advanced Pancreatic Adenocarcinoma Using Intratumoral Injection of CYL-02 in Combination With Gemcitabine
Status: Completed, Estimated PCD: 2022-06-30
Product
CYL-02
Clinical trial
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
Paclitaxel Protein Bound
Product
nab-Paclitaxel
Drug
lenalidomide
Clinical trial
Radiotherapy Plus Chemotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer Who Are Not Refractory to Chemotherapy
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-10
Product
BMS-986340
Clinical trial
CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2026-07-15
Product
Namodenoson
Clinical trial
A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Phase Ib Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
Anti-EGFR-bispecific antibody armed activated T-cells
Clinical trial
A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Status: Recruiting, Estimated PCD: 2027-04-01
Product
ESK981
Clinical trial
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Recruiting, Estimated PCD: 2025-12-01
Product
INBRX-109
Clinical trial
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Anetumab Ravtansine
Drug
Lurbinectedin
Product
Pemetrexed
Product
TMZ
Clinical trial
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-11-01
Product
SGN-MesoC2
Clinical trial
Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Drug
NALIRIFOX